Hepatocyte growth factor and transforming growth factor β1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis

Arthritis and Rheumatism

Volumn 54, Issue 11, 2006, Pages 3633-3639

  Capuano, Anna ^a   Costanzi, Stefano ^a   Peluso, Giusy ^a   Zannoni, Gianfranco ^a   Vellone, Valerio Gaetano ^a   Gremese, Elisa ^a   Zoli, Angelo ^a   Scott, Cathryn ^b   Beltrami, Carlo Alberto ^b   Romano, Giulio ^b   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; SCATTER FACTOR; STEROID; TRANSFORMING GROWTH FACTOR BETA1;

ACTIVITY INDEX; ADULT; ARTICLE; CHRONICITY INDEX; CLINICAL ARTICLE; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; GLOMERULUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY TUBULE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PATIENT MONITORING; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CYCLOPHOSPHAMIDE; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33750956944     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22192     Document Type: Article

References (23)

1. Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contribution of clinical and histologic data. Kidney Int 1994;45:544-50.
2. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047-53.
3. Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
4. Ciruelo E, de la Cruz J, Lopez I, Gomez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996;39:2028-34.
5. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40.
6. Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP, et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001;59:304-16.
7. Hill GS, Delahousse M, Nochy D, Thervet E, Vrtovsnik F, Remy P, et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int 2002;61:2176-86.
8. Dixey J, Solymossy C, Young A. Early RA study: is it possible to predict radiological damage in early RA? A report on the occurrence, progression and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol Suppl 2004;69:48-54.
9. D'Amico G, Ferrario F, Rastaldi MP. Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. Am J Kidney Dis 1995;26:124-32.
10. Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, Nakamura T. Reciprocal balance of HGF and TGFβ1 in renal fibrosis in mice. Kidney Int 2000;57:937-48.
11. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanism of action. Am J Physiol Renal Physiol 2004;287:F7-16.
12. Kopp JB, Factor VM, Mozes M, Nagy P, Sanerson N, Bottinger EP, et al. Transgenic mice with increased plasma levels of TGFβ1 develop progressive renal disease. Lab Invest 1996;74:991-1003.
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
14. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73:931-4.
15. Illei GG, Austin HA III, Crane M, Collins L, Gourely MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
16. Yoo CW, Kim MK, Lee HS. Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol Dial Transplant 2000;15:1604-8.
17. Leaker B, Fairely KF, Dowling J, Kinkaid-Smith P. Lupus nephritis: clinical and pathological correlations. Q J Med 1987;62:163-79.
18. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ, for the Lupus Nephritis Collaborative Study Group. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Am J Kidney Dis 1993;21:374-7.
19. Cameron JS. Tubular and interstitial factors in the progression of glomerulonephritis. Pediatr Nephrol 1992;6:292-303.
20. Hill GS, Delahousse M, Nochy D, Tomkiewicz E, Remy P, Mignon F, et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000;58:1160-73.
21. Hill GS, Delahouse M, Nochy D, Mandet C, Bariety J. Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int 2001;60:1893-903.
22. Esdaile JM, Federgreen W, Quintal H, Suissa S, Hayslett JP, Kashgarian M. Predictors of one year outcome in lupus nephritis: the importance of renal biopsy. Q J Med 1991;81:907-18.
23. D'Amico G. Tubulointerstitium as predictor of progression of glomerular disease. Nephron 1999;83:289-95.